These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22999811)

  • 41. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
    Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
    Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
    Oresković S; But I; Banović M; Goldstajn MS
    Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
    Paquette A; Gou P; Tannenbaum C
    J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
    Aaron LE; Morris TJ; Jahshan P; Reiz JL
    Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.